Klaus Pantel
Professor Pantel did his MD at the University of Cologne in 1986, Dr. Med. at the University of Cologne in 1987 and Dr. Med. Habil. at the Ludwig-Maximillians-Universitaet in 1995. He is currently director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf.
Main content
Professor Pantel has done pioneer work聽in the field of cancer micrometastasis,聽circulating tumor cells and circulating聽nucleic acids (ctDNA, microRNAs). He聽coordinates the European TRANSCAN聽group 鈥淐TC-SCAN鈥, the European IMI聽consortium CANCERID () on blood-based 鈥淟iquid Biopsies鈥 and聽has established a clinical micrometastasis聽research network at the University Cancer聽Center Hamburg with a clear focus on聽diagnosis and treatment of solid tumors.
Professor Pantel鈥檚 expertise is particularly聽on disseminating tumor cells as a biomarker聽of treatment efficacy. This work聽provides new insights into the biology of聽early tumor cell dissemination in cancer聽patients with particular emphasis on the聽identification of the putative metastatic聽founder cells (鈥渟tem cells鈥) and the regulation聽of cancer dormancy responsible for聽late relapses in breast cancer patients.
Professor Pantel has a broad collaboration聽with CCBIO, most recently in a prospective聽non-randomized phase I trial of聽metastatic castration resistant prostate聽cancer. Here, he collaborated among others聽with Liv Cecilie Vestrheim Thomsen,聽Waqas Azeem, Lars A. Akslen, Bj酶rn聽Tore Gjertsen and Karl-Henning Kalland.聽The trial shows that dendritic cell based聽cryoimmunotherapy associates with聽clinical variables and changes in T-cell聽receptor expression.
Professor Pantel was聽also co-organizer of the CCBIO Satellite聽Symposium on Liquid Biopsies which聽took place the day before the CCBIO聽Annual Symposium, May 22nd 2018 at聽Solstrand outside of Bergen.
